Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Takeda will seek an external partner to leverage its cell therapy platform technologies
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Subscribe To Our Newsletter & Stay Updated
